Cytosorbents Corporation (CTSO): Price and Financial Metrics


Cytosorbents Corporation (CTSO): $2.37

0.04 (+1.72%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CTSO POWR Grades

  • CTSO scores best on the Sentiment dimension, with a Sentiment rank ahead of 75.66% of US stocks.
  • CTSO's strongest trending metric is Growth; it's been moving up over the last 177 days.
  • CTSO ranks lowest in Quality; there it ranks in the 11th percentile.

CTSO Stock Summary

  • CTSO has a market capitalization of $101,671,216 -- more than approximately merely 19.05% of US stocks.
  • Over the past twelve months, CTSO has reported earnings growth of 152.41%, putting it ahead of 90.28% of US stocks in our set.
  • Revenue growth over the past 12 months for CYTOSORBENTS CORP comes in at -18.63%, a number that bests just 9.64% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to CYTOSORBENTS CORP, a group of peers worth examining would be AYRO, TRVN, FCEL, SONM, and APPN.
  • Visit CTSO's SEC page to see the company's official filings. To visit the company's web site, go to www.cytosorbents.com.

CTSO Valuation Summary

  • In comparison to the median Healthcare stock, CTSO's EV/EBIT ratio is 119.19% lower, now standing at -1.9.
  • CTSO's price/earnings ratio has moved down 0.9 over the prior 183 months.

Below are key valuation metrics over time for CTSO.

Stock Date P/S P/B P/E EV/EBIT
CTSO 2023-01-20 2.5 2.3 -2.2 -1.9
CTSO 2023-01-19 2.6 2.4 -2.2 -1.9
CTSO 2023-01-18 2.6 2.4 -2.2 -1.9
CTSO 2023-01-17 2.7 2.5 -2.4 -2.1
CTSO 2023-01-13 2.7 2.5 -2.4 -2.1
CTSO 2023-01-12 2.6 2.4 -2.3 -2.0

CTSO Growth Metrics

    Its 4 year net cashflow from operations growth rate is now at -111.03%.
  • Its 3 year revenue growth rate is now at 81.19%.
  • Its 3 year cash and equivalents growth rate is now at 127.56%.
Over the past 15 months, CTSO's revenue has gone down $9,044,774.

The table below shows CTSO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 36.08053 -28.38555 -41.35347
2022-06-30 37.72959 -25.78428 -35.55892
2022-03-31 41.2581 -19.78053 -29.35722
2021-12-31 43.16553 -14.0056 -24.55865
2021-09-30 44.33911 -9.571806 -15.92936
2021-06-30 45.1253 -8.722604 -10.3628

CTSO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTSO has a Quality Grade of D, ranking ahead of 21.38% of graded US stocks.
  • CTSO's asset turnover comes in at 0.475 -- ranking 101st of 186 Medical Equipment stocks.
  • NVCR, CUTR, and HAE are the stocks whose asset turnover ratios are most correlated with CTSO.

The table below shows CTSO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.475 0.759 -0.637
2021-03-31 0.518 0.734 -0.733
2020-12-31 0.570 0.730 -0.516
2020-09-30 0.648 0.709 -0.613
2020-06-30 0.857 0.706 -0.892
2020-03-31 0.884 0.719 -0.911

CTSO Price Target

For more insight on analysts targets of CTSO, see our CTSO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.60 Average Broker Recommendation 1.33 (Strong Buy)

CTSO Stock Price Chart Interactive Chart >

Price chart for CTSO

CTSO Price/Volume Stats

Current price $2.37 52-week high $4.15
Prev. close $2.33 52-week low $1.03
Day low $2.32 Volume 49,600
Day high $2.40 Avg. volume 99,556
50-day MA $1.61 Dividend yield N/A
200-day MA $1.89 Market Cap 103.42M

Cytosorbents Corporation (CTSO) Company Bio


CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.


CTSO Latest News Stream


Event/Time News Detail
Loading, please wait...

CTSO Latest Social Stream


Loading social stream, please wait...

View Full CTSO Social Stream

Latest CTSO News From Around the Web

Below are the latest news stories about CYTOSORBENTS CORP that investors may wish to consider to help them evaluate CTSO as an investment opportunity.

CytoSorbents Announces Health Canada Regulatory Approval For Pivotal STAR-T Trial

PRINCETON, N.J., Jan. 23, 2023 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has…

PR Newswire | January 23, 2023

CytoSorbents says Canada cleared pivotal study for anti-bleeding technology

CytoSorbents (CTSO) announced Monday that Health Canada approved patient enrollment in the country for its pivotal STAR-T trial for anti-bleeding technology. Read the full story here.

Seeking Alpha | January 23, 2023

CytoSorbents Appoints Irina B. Kulinets, PhD, as Senior Vice President of Global Regulatory Affairs

CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that it has appointed Irina B. Kulinets, Ph.D., as Senior Vice President of Global Regulatory Affairs. Dr. Kulinets brings more than 30 years of experience in regulatory affairs and clinical research of medical devices, biologics, and combination products in multiple t

Yahoo | January 17, 2023

Can Cytosorbents (NASDAQ:CTSO) Afford To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | January 12, 2023

CytoSorbents Receives $5 Million in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement

Non-dilutive debt capital at market favorable terms strengthens the balance sheet and provides additional working capital to fund key clinical and commercial initiatives CytoSorbents Corporation, a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology,… The post CytoSorbents Receives $5 Million in Non-Dilutive Debt Financing from Bridge Bank and Extends Loan Agreement appeared first on GlobalFinTechSeries .

Global FinTech Series | December 30, 2022

Read More 'CTSO' Stories Here

CTSO Price Returns

1-mo 52.90%
3-mo 26.74%
6-mo 1.28%
1-year -32.09%
3-year -52.22%
5-year -68.82%
YTD 52.90%
2022 -63.01%
2021 -47.43%
2020 107.01%
2019 -52.35%
2018 24.31%

Continue Researching CTSO

Want to see what other sources are saying about Cytosorbents Corp's financials and stock price? Try the links below:

Cytosorbents Corp (CTSO) Stock Price | Nasdaq
Cytosorbents Corp (CTSO) Stock Quote, History and News - Yahoo Finance
Cytosorbents Corp (CTSO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7944 seconds.